Gerber of Sutro Biopharma buys $13,606 in STRO stock

Hans-Peter Gerber, Chief Scientific Officer at Sutro Biopharma Inc (NASDAQ:STRO), purchased 17,000 shares of common stock on October 15, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The purchase comes as the stock has declined nearly 58% year-to-date and is trading at $0.78, significantly below its 52-week high of $4.60. The total value of the purchase was $13,606.

The prices paid for the shares ranged from $0.7932 to $0.8015. Following the transaction, Gerber directly owns 71,832 shares of Sutro Biopharma . According to InvestingPro analysis, the stock appears undervalued at current levels, and the company maintains a strong balance sheet with more cash than debt. Get deeper insights into insider trading patterns and 12 additional ProTips with an InvestingPro subscription.

In other recent news, Sutro Biopharma has announced an organizational restructuring that will reduce its workforce by approximately one-third. This move is part of the company’s efforts to prioritize its antibody drug conjugate (ADC) programs and research collaborations, with the goal of extending its financial runway into at least mid-2027. The restructuring is expected to be supported by near-term milestone payments, which will carry the company beyond several key milestones, including the planned announcement of initial clinical data from its STRO-004 program. In addition, Sutro Biopharma has partnered with the U.S. Food and Drug Administration to develop reference materials for ADCs, aiming to improve regulatory standards and enhance analytical methods.

Meanwhile, Citizens JMP analyst Reni Benjamin has reiterated a Market Perform rating on Sutro Biopharma following the company’s second quarter 2025 earnings announcement. As part of its corporate updates, Sutro Biopharma reaffirmed plans to file an Investigational New Drug application for STRO-004 in the second half of 2025. These developments indicate the company’s ongoing commitment to advancing its ADC programs and strategic collaborations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.